Jeffrey T. Schouten

1.8k total citations
31 papers, 931 citations indexed

About

Jeffrey T. Schouten is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jeffrey T. Schouten has authored 31 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 12 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Jeffrey T. Schouten's work include HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (8 papers). Jeffrey T. Schouten is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (8 papers). Jeffrey T. Schouten collaborates with scholars based in United States, South Africa and Puerto Rico. Jeffrey T. Schouten's co-authors include James L. Weese, Paul P. Carbone, Judith S. Currier, Caroline Sabin, Paul E. Sax, Marek Smieja, Jens Lundgren, Andrew Carr, Daniel B. Klein and Scott R. Rosas and has published in prestigious journals such as JAMA, Circulation and PLoS ONE.

In The Last Decade

Jeffrey T. Schouten

29 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey T. Schouten United States 16 408 347 254 154 121 31 931
Brian P. Mulhall Australia 18 80 0.2× 254 0.7× 171 0.7× 444 2.9× 138 1.1× 40 1.2k
Alexander Monto United States 22 81 0.2× 129 0.4× 84 0.3× 1.3k 8.6× 127 1.0× 62 1.8k
Barbara L. Kroner United States 27 72 0.2× 346 1.0× 328 1.3× 347 2.3× 102 0.8× 75 2.5k
Shehnaz K. Hussain United States 21 49 0.1× 88 0.3× 122 0.5× 327 2.1× 121 1.0× 53 1.3k
JM Kaldor Australia 16 42 0.1× 284 0.8× 97 0.4× 299 1.9× 40 0.3× 26 796
Jeroen G. Noordzij Netherlands 15 67 0.2× 80 0.2× 22 0.1× 248 1.6× 257 2.1× 29 1.2k
Caroline Dickens South Africa 15 59 0.1× 97 0.3× 24 0.1× 209 1.4× 85 0.7× 67 988
J. van der Lelie Netherlands 19 81 0.2× 95 0.3× 48 0.2× 138 0.9× 78 0.6× 42 1.8k
D. Lacoste France 19 116 0.3× 326 0.9× 198 0.8× 341 2.2× 91 0.8× 77 897
Anna E. Coghill United States 23 81 0.2× 214 0.6× 61 0.2× 558 3.6× 369 3.0× 83 1.8k

Countries citing papers authored by Jeffrey T. Schouten

Since Specialization
Citations

This map shows the geographic impact of Jeffrey T. Schouten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey T. Schouten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey T. Schouten more than expected).

Fields of papers citing papers by Jeffrey T. Schouten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey T. Schouten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey T. Schouten. The network helps show where Jeffrey T. Schouten may publish in the future.

Co-authorship network of co-authors of Jeffrey T. Schouten

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey T. Schouten. A scholar is included among the top collaborators of Jeffrey T. Schouten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey T. Schouten. Jeffrey T. Schouten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karita, Helen C. Stankiewicz, John Lin, Jeffrey T. Schouten, et al.. (2024). Methylation markers for anal cancer screening: A repeated cross‐sectional analysis of people living with HIV, 2015–2016. International Journal of Cancer. 155(6). 1091–1100. 1 indexed citations
2.
Karita, Helen C. Stankiewicz, Amalia Magaret, Constance Mao, et al.. (2019). Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA). JAMA Network Open. 2(4). e190819–e190819. 23 indexed citations
3.
Morar, Neetha S., et al.. (2014). Implementing Community Involvement in National Institutes of Health (NIH) HIV/AIDS Clinical Trials Networks. AIDS Research and Human Retroviruses. 30(S1). A107–A107. 4 indexed citations
4.
Krishnan, Supriya, Jeffrey T. Schouten, Benjamin Atkinson, et al.. (2014). Changes in Metabolic Syndrome Status After Initiation of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(1). 73–80. 24 indexed citations
5.
Rosas, Scott R., et al.. (2014). Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials. Clinical Trials. 11(5). 553–559. 5 indexed citations
6.
Godfrey, Catherine & Jeffrey T. Schouten. (2013). Infection Control Best Practices in Clinical Research in Resource-Limited Settings. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(Supplement 1). S15–S18. 4 indexed citations
7.
Rosas, Scott R., et al.. (2013). Assessing the challenges of multi‐scope clinical research sites: an example from NIH HIV/AIDS clinical trials networks. Journal of Evaluation in Clinical Practice. 20(2). 149–157. 3 indexed citations
8.
Smurzynski, Marlene, Kunling Wu, Jeffrey T. Schouten, et al.. (2013). Factors associated with remaining on initial randomized efavirenz-containing regimens. AIDS. 27(12). 1887–1897. 2 indexed citations
9.
Schouten, Jeffrey T. & Joshua T. Schiffer. (2012). Equal HIV-1 Decay Kinetics in HSV-2–Infected and HSV-2–Uninfected Clinical Trial Participants Treated With Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(1). 68–71. 1 indexed citations
10.
Kagan, Jonathan, et al.. (2012). Community-Researcher Partnerships at NIAID HIV/AIDS Clinical Trials Sites: Insights for Evaluation and Enhancement. Progress in community health partnerships. 6(3). 311–320. 18 indexed citations
11.
Landovitz, Raphael J., Sengeziwe Sibeko, Magdalena E. Sobieszczyk, et al.. (2012). Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS. 27(7). 1119–1128. 1 indexed citations
12.
Krishnan, Supriya, Jeffrey T. Schouten, Benjamin Atkinson, et al.. (2012). Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 61(3). 381–389. 61 indexed citations
13.
Krishnan, Supriya, Jeffrey T. Schouten, Denise L. Jacobson, et al.. (2011). Incidence of Non-AIDS-Defining Cancer in Antiretroviral Treatment-Naïve Subjects after Antiretroviral Treatment Initiation: An ACTG Longitudinal Linked Randomized Trials Analysis. Oncology. 80(1-2). 42–49. 32 indexed citations
14.
Schouten, Jeffrey T., Amy Krambrink, Heather J. Ribaudo, et al.. (2010). Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095. Clinical Infectious Diseases. 50(5). 787–791. 20 indexed citations
15.
Heath, Laura, Alan J. Fox, Jan McClure, et al.. (2009). Evidence for Limited Genetic Compartmentalization of HIV-1 between Lung and Blood. PLoS ONE. 4(9). e6949–e6949. 29 indexed citations
16.
Gulick, Roy M., Christina M. Lalama, Heather J. Ribaudo, et al.. (2007). Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 21(7). 813–823. 16 indexed citations
17.
Schouten, Jeffrey T., et al.. (2006). A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people. BMC Infectious Diseases. 6(1). 28–28. 37 indexed citations
18.
Mulligan, Kathleen, Yang Yang, David Wininger, et al.. (2006). Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 21(1). 47–57. 75 indexed citations
19.
Schouten, Jeffrey T.. (1996). FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.. PubMed. 8(1). 7–8. 6 indexed citations
20.
Schouten, Jeffrey T.. (1986). Operative therapy for pancreatic carcinoma. The American Journal of Surgery. 151(5). 626–630. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian P. Mulhall Breakdown of academic impact, for papers by Alexander Monto Breakdown of academic impact, for papers by Barbara L. Kroner Breakdown of academic impact, for papers by Shehnaz K. Hussain Breakdown of academic impact, for papers by JM Kaldor Breakdown of academic impact, for papers by Jeroen G. Noordzij Breakdown of academic impact, for papers by Caroline Dickens Breakdown of academic impact, for papers by J. van der Lelie Breakdown of academic impact, for papers by D. Lacoste Breakdown of academic impact, for papers by Anna E. Coghill
Rankless by CCL
2026